Department of Health and Human Services

Part 1. Overview Information

Participating Organization(s)

National Institutes of Health (NIH)

Components of Participating Organizations

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Funding Opportunity Title
National Centers for Metabolic Phenotyping in Live Models of Obesity and Diabetes (MPMOD) (U2C - Clinical Trial Not Allowed)
Activity Code

U2C Resource-Related Research Multi-Component Projects and Centers Cooperative Agreements

Announcement Type
New
Related Notices

  • January 07, 2021 - Notice of Change to Award Information for RFA-DK-21-027. See Notice NOT-DK-22-008.
  • October 28, 2021 - Reminder: FORMS-G Grant Application Forms & Instructions Must be Used for Due Dates On or After January 25, 2022 - New Grant Application Instructions Now Available. See Notice NOT-OD-22-018.
  • September 13, 2021 - Updates to the Non-Discrimination Legal Requirements for NIH Recipients. See Notice NOT-OD-21-181.
  • August 5, 2021 - New NIH "FORMS-G" Grant Application Forms and Instructions Coming for Due Dates on or after January 25, 2022. See Notice NOT-OD-21-169
  • August 5, 2021 - Update: Notification of Upcoming Change in Federal-wide Unique Entity Identifier Requirements. See Notice NOT-OD-21-170
  • April 20, 2021 - Expanding Requirement for eRA Commons IDs to All Senior/Key Personnel. See Notice NOT-OD-21-109

Funding Opportunity Announcement (FOA) Number
RFA-DK-21-027
Companion Funding Opportunity
RFA-DK-21-035 , U24 Resource-Related Research Project (Cooperative Agreements)
Assistance Listing Number(s)
93.847
Funding Opportunity Purpose

This Funding Opportunity Announcement invites applications for National Centers for Metabolic Phenotyping in Live Models of Obesity and Diabetes (MPMOD). The Centers will provide complex metabolic, physiologic and behavioral phenotyping and consulting services to characterize living mouse models on a fair fee-for-service basis. Tests that do not require living animals will not be supported by this initiative. MPMODs may also provide special mouse models for study at the Center or for distribution, such as mice that have undergone bariatric surgery or implanted catheters. Services are provided with equal priority to investigators inside and outside the home institution, at similar cost, to study the heterogeneity, pathogenesis, and metabolic and physiologic consequences of diabetes and obesity. The MPMOD Centers will work together as a consortium, supported by a Coordinating Unit, to improve access to high quality consultation and phenotyping for metabolic disease research conducted in mice; establish outreach/advertising to potential clients; and be synergistic and cost-effective, including developing common test protocols and eliminating overlap where appropriate. An important goal of this consortium will be to enable underrepresented PIs and those from small research institutions that traditionally have not received significant research funding and/or have historically served under-represented populations to produce outstanding results and better compete for funding.

Key Dates

Posted Date
November 29, 2021
Open Date (Earliest Submission Date)
February 08, 2022
Letter of Intent Due Date(s)

February 08, 2022

Application Due Dates Review and Award Cycles
New Renewal / Resubmission / Revision (as allowed) AIDS Scientific Merit Review Advisory Council Review Earliest Start Date
March 08, 2022 Not Applicable Not Applicable July 2022 October 2022 December 2022

All applications are due by 5:00 PM local time of applicant organization. All types of non-AIDS applications allowed for this funding opportunity announcement are due on the listed date(s).

Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Expiration Date
March 09, 2022
Due Dates for E.O. 12372

Not Applicable

Required Application Instructions

It is critical that applicants follow the Multi-Project (M) Instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise (in this FOA or in a Notice from the NIH Guide for Grants and Contracts). Conformance toall requirements (both in the Application Guide and the FOA) is required and strictly enforced. Applicants must read and follow all application instructions in the Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the Application Guide, follow the program-specific instructions. Applicationsthat do not comply with these instructions may be delayed or not accepted for review,

There are several options available to submit your application through Grants.gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.

  1. Use the NIH ASSIST system to prepare, submit and track your application online.
  2. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants.gov and eRA Commons to track your application. Check with your institutional officials regarding availability.



  3. Table of Contents

Part 2. Full Text of Announcement

Section I. Funding Opportunity Description

Background

Study sections and journal editors typically require evidence that pathways under study in diabetes and obesity research affect function and health in the living animal, yet the required complex physiologic, metabolic, and behavioral measurements are not available at all research institutions. The MPMOD is designed as an outwardly-facing consortium of service cores that collaborate to provide reduced-cost consultation and metabolic, physiologic and behavioral phenotyping tests on live animals to all US academic biomedical researchers. MPMOD will:
 

1. Serve the US academic research community that uses mice to study diabetes and obesity by providing metabolic, physiologic, and behavioral phenotyping on live mice, as well as expert advice in mouse models, experiment design, data analysis, and data interpretation. Centers will serve clients from outside as well as inside their home institution without bias and at similar cost, and collaborate to provide a wide array of tests and expert advice while avoiding unnecessary overlap.

2. Work toward health equity and diversity in the US biomedical research enterprise by supporting underrepresented minority investigators to succeed in biomedical research in the areas of diabetes and obesity, via resources such as test services, pilot funding, expert advice on experimental design, and/or short internships at a MPMOD to learn test technologies. Together, these consortium activities constitute the MPMOD Vibrant program which will be supported by the Phenotyping Centers and the Coordinating Unit.

3. Serve Rigor and Reproducibility in research by a) developing and sharing validated protocols for phenotyping live mice; b) providing difficult experimental tests conducted by experts with a high degree of standardization and quality control, to PIs who would otherwise not be able to conduct or afford them; and c) sharing technologies and providing web-based tools for gold-standard approaches in experimental methods and data analysis. This will help train new physiologists and metabolic experts.

4. Develop standardized data formats and storage guidelines for complex data, including metadata, for sharing with clients and the public as appropriate, and employ unique Research Resource identifiers (RRID), Digital Object Identifiers (DOI), and other best practices directed by DKNet.
 

Consortium Structure

MPMOD will consist of cooperating Phenotyping Centers (PCs) and a Coordinating Unit (CU), with guidance provided by a Steering Committee (SC) and External Scientific Panel (ESP). The CU will 1) provide logistical and administrative support, 2) distribute funds and oversee financial management of the MPMOD Vibrant program, 3) provide and maintain the MPMOD website, which may contain web-based educational, data-sharing, and business tools, and 4) promote the consortium via advertising/outreach. The CU may also share similar resources with other NIDDK-funded Centers programs.
 

Phenotyping Center Structure

Individual MPMOD PCs will have a Center Program Director/Principal Investigator (PD/PI) and an Associate Director, who would become the Center Director if the original Director is unable to continue. The PC will be overseen by a local Steering Committee, and will consist of an Administrative Core, an Animal Core, and up to four Phenotyping Cores.

 

Phenotyping Cores

Phenotyping Cores will serve investigators from outside the recipient institution with the same priority and at similar cost as those from within. Each PC will have one to four Phenotyping Cores, each headed by a Core Director, where tests will be performed on submitted living mouse models relevant for research in diabetes, obesity, and other complex metabolic diseases. Phenotyping Core personnel will design or adapt, standardize, and validate a variety of tests to be conducted on living mice submitted by clients. Phenotyping Cores are expected to keep test offerings relevant and state of the art. These tests will be provided on a fee-for-service basis. Phenotyping Cores are expected to provide unique and powerful tests that are in demand, yet not widely available to the investigator community. Phenotyping Cores may provide standard or customized tests for various models, and should propose a method to provide advice/consultation services to clients regarding study design, appropriate outcome measures and data interpretation. Each Phenotyping Core should have a fee schedule for its tests, and the PC fee schedules should include consultation on experimental design as an important part of its offerings.
 

Applicants should consider quality control measures, data management, presentation, and communication with clients, and data sharing. The MPMOD SC may choose to support a common database at the CU for these purposes. Test protocols must be documented and shared publicly on the MPMOD website, which will be provided by the CU. PCs will work closely with others in the consortium to take full advantage of collective strengths to provide the best possible range of tests for customers, realize cost-effectiveness where possible, and standardize common measures where appropriate.
 

PCs will support phenotyping of live mice only. Examples of proposed services include, but are not limited to:

  • Measures of glucose, lipid and protein metabolism, insulin resistance, body composition, nutrient absorption, action of insulin, glucagon, leptin, gut peptides and other hormones and signals;
  • Organ dysfunction associated with diabetes, obesity or metabolic diseases;
  • Energy balance and thermogenesis;
  • Hypothalamic function or other aspects of nervous system activity important for metabolic regulation or energy homeostasis;
  • Cognition, learning, anxiety, depression, etc., as a consequence of metabolic disease;
  • Digestive system and liver function, including bariatric surgery procedures to dissect relationships between gut function and metabolic status;
  • Behaviors affected by or interacting with diabetes and obesity, including feeding, physical activity, sleep, and circadian rhythms;
  • PET, NMR, mass spectrometric, or other isotopic studies of metabolic pathway flux;
  • Whole body or organ balance tracer measurements of uptake and production of carbohydrate, protein, or amino acids;
  • Assessment of mitochondrial function in vivo;
  • Use of exercise or other physiologic stressors to explore or uncover metabolic phenotypes (temperature, exogenous hormones, altered diet, time-limited access to diet);
  • Physiologic measurements, such as blood pressure, core temperature, cardiac output, regional blood flow, or nerve function;
  • Surgical preparations, such as bariatric surgeries, placement of indwelling catheters, lymph fistula, etc.
     

Animal Core

An application must propose an Animal Core, as all MPMOD tests are to be done on live animals. The Animal Core will receive, house, feed, monitor, and maintain the health of submitted mice for the duration required for the phenotyping exam. In most cases animals will not be returned to the originating institution. However, applicants can propose to provide special animal models for shipment to client institutions, such as bariatric surgery models or mice with surgically implanted cannula.
 

Administrative Core

The Director of the Administrative Core would in most cases be the MPMOD Center Director. The Administrative Core will manage budgets, staff, workflow, and client interactions, collect fees for services, and manage business and data records. It will oversee collaboration with other MPMOD PCs.
 

Local Steering Committee

A local Steering Committee will assist the PIs/PDs in making decisions regarding test offerings and development, budget and prioritization decisions, and help adjudicate client disputes. At least one member should be a senior researcher at the institution who is not directly involved in the MPMOD. Applications should not include the names of members of the local Steering Committee.
 

Data Ownership and Authorship

The MPMODs are designed to provide service at a fair cost to the research community, not to fund the personal or collaborative research programs of PC staff. Investigators who send their mice to an MPMOD should be confident that phenotyping data subsequently provided by the MPMOD belongs to them and does not obligate them to any kind of collaboration, nor are they expected to share authorship with PC personnel when these phenotyping data are published. This is especially true for routine tests that are easily accomplished with minimal scientific or intellectual input from PC personnel, beyond the standard planning and advice needed to decide which tests are appropriate. In order to accomplish this, investigators seeking phenotyping services and PC personnel are required to sign a Conditions of Use Statement (COU), provided at the MPMOD website, that verifies that phenotyping data generated by the MPMOD PC belongs exclusively to the investigator that owns the mouse and his/her institution, and not to the PC. If a submitting investigator and an MPMOD staff member decide to form a true collaboration based on equitably shared amounts of time, funds and scientific input, their collaborative work must be funded by non-MPMOD funds, and the partnership should be documented by signed letters deposited in the Administrative Core. Although the phenotypic data belongs to the MPMOD client, he/she may be expected to allow it to be added to a MPMOD database. If so, these data along with descriptive metadata may be released to the public by MPMOD either after publication or a reasonable time after completion of the tests unless the client requests additional time.
 

Consortium Activities

The applicant must agree to active participation in consortium-wide activities as deemed necessary by appropriate oversight committees.  At the time of publication of this FOA, these activities include:
 

MPMOD Vibrant Program

The MPMOD PCs and the CU will be expected to develop an MPMOD Vibrant program aimed at providing pilot funding, phenotyping services or other resources, and training and advice regarding experimental design to early career scientists, particularly those from underrepresented groups such as minorities, or from small research institutions that traditionally have not received significant research funding and/or have historically served under-represented populations. These resources are expected to improve the ability of these researchers to compete for independent funding. Vibrant activities should contribute to a diverse, high quality national biomedical research force, eventually helping to reduce US health disparities. Applications can describe activities that could comprise this program. Funding for pilot studies and outreach will be in the CU budget, but funding for other elements (waived test fees, structured or unstructured training at the centers, consultation, other mentoring) would be the responsibility of the PCs.
 

MPMOD Website and Web-based Tools

The CU will provide an MPMOD website, with web-based tools for outreach and to help manage the business, data, and other consortium activities. Protocols for all tests will be posted on the MPMOD website. PCs may post other tools developed to help clients and other researchers with metabolic research in mice.

See Section VIII. Other Information for award authorities and regulations.

Section II. Award Information

Funding Instrument

Cooperative Agreement: A support mechanism used when there will be substantial Federal scientific or programmatic involvement. Substantial involvement means that, after award, NIH scientific or program staff will assist, guide, coordinate, or participate in project activities. See Section VI.2 for additional information about the substantial involvement for this FOA.

Application Types Allowed
New

The OER Glossary and the SF424 (R&R) Application Guide provide details on these application types. Only those application types listed here are allowed for this FOA.

Clinical Trial?

Not Allowed: Only accepting applications that do not propose clinical trials.

Need help determining whether you are doing a clinical trial?

Funds Available and Anticipated Number of Awards

NIDDK intends to commit $2,010,000 in FY 2023 to fund three awards.

Award Budget

Application budgets are limited to $425,000 Direct Costs, but need to reflect the actual needs of the proposed project.

Award Project Period

The maximum project period is 5 years.

NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this FOA.

Section III. Eligibility Information

1. Eligible Applicants

Eligible Organizations

Higher Education Institutions

  • Public/State Controlled Institutions of Higher Education
  • Private Institutions of Higher Education

The following types of Higher Education Institutions are always encouraged to apply for NIH support as Public or Private Institutions of Higher Education:

  • Hispanic-serving Institutions
  • Historically Black Colleges and Universities (HBCUs)
  • Tribally Controlled Colleges and Universities (TCCUs)
  • Alaska Native and Native Hawaiian Serving Institutions
  • Asian American Native American Pacific Islander Serving Institutions (AANAPISIs)

Nonprofits Other Than Institutions of Higher Education

  • Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education)
  • Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education)

For-Profit Organizations

  • Small Businesses
  • For-Profit Organizations (Other than Small Businesses)

Local Governments

  • State Governments
  • County Governments
  • City or Township Governments
  • Special District Governments
  • Indian/Native American Tribal Governments (Federally Recognized)
  • Indian/Native American Tribal Governments (Other than Federally Recognized)

Federal Governments

  • Eligible Agencies of the Federal Government
  • U.S. Territory or Possession
Foreign Institutions

Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply.

Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.

Foreign components, as defined in the NIH Grants Policy Statement, are allowed. 

Required Registrations

Applicant organizations

Applicant organizations must complete and maintain the following registrations as described in the SF 424 (R&R) Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible. The NIH Policy on Late Submission of Grant Applications states that failure to complete registrations in advance of a due date is not a valid reason for a late submission.

  • Dun and Bradstreet Universal Numbering System (DUNS) - All registrations require that applicants be issued a DUNS number. After obtaining a DUNS number, applicants can begin both SAM and eRA Commons registrations. The same DUNS number must be used for all registrations, as well as on the grant application.
  • System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually. The renewal process may require as much time as the initial registration. SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code.
  • eRA Commons - Applicants must have an active DUNS number to register in eRA Commons. Organizations can register with the eRA Commons as they are working through their SAM or Grants.gov registration, but all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application.
  • Grants.gov – Applicants must have an active DUNS number and SAM registration in order to complete the Grants.gov registration.

Program Directors/Principal Investigators (PD(s)/PI(s))

All PD(s)/PI(s) must have an eRA Commons account.  PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.

Eligible Individuals (Program Director/Principal Investigator)

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

2. Cost Sharing

This FOA does not require cost sharing as defined in the NIH Grants Policy Statement.

3. Additional Information on Eligibility

Number of Applications

Applicant organizations may submit more than one application, provided that each application is scientifically distinct.

The NIH will not accept duplicate or highly overlapping applications under review at the same time, per 2.3.7.4 Submission of Resubmission Application. This means that the NIH will not accept:

  • A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
  • A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.
  • An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).

Section IV. Application and Submission Information

1. Requesting an Application Package

The application forms package specific to this opportunity must be accessed through ASSIST or an institutional system-to-system solution. A button to apply using ASSIST is available in Part 1 of this FOA. See your administrative office for instructions if you plan to use an institutional system-to-system solution.

2. Content and Form of Application Submission

It is critical that applicants follow the Multi-Project (M) Instructions in the SF424 (R&R) Application Guide, except where instructed in this funding opportunity announcement to do otherwise and where instructions in the Application Guide are directly related to the Grants.gov downloadable forms currently used with most NIH opportunities. Conformance to the requirements in the Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review.

Letter of Intent

Although a letter of intent is not required, is not binding, and does not enter into the review of a subsequent application, the information that it contains allows IC staff to estimate the potential review workload and plan the review.

By the date listed in Part 1. Overview Information, prospective applicants are asked to submit a letter of intent that includes the following information:

  • Descriptive title of proposed activity
  • Name(s), address(es), and telephone number(s) of the PD(s)/PI(s)
  • Names of other key personnel
  • Participating institution(s)
  • Number and title of this funding opportunity

The letter of intent should be sent to:

John Connaughton, Ph.D.
Chief, Scientific Review Branch
Telephone: 301-594-7797
Email: NIDDKletterofintent@mail.nih.gov

Page Limitations

All page limitations described in the SF424 Application Guide and the Table of Page Limits must be followed.

Component Component Type for Submission Page Limit Required/Optional Minimum Maximum
Overall Overall 12 Required 1 1
Admin Core Admin Core 12 Required 1 1
Animal Core Core 12 Required 1 1
Phenotyping Core Phenotyping Core 12 Required 1 4

Instructions for the Submission of Multi-Component Applications

The following section supplements the instructions found in the SF424 (R&R) Application Guide, and should be used for preparing a multi-component application.

The application should consist of the following components:

  • Overall: Required
  • Administrative Core: Required
  • Animal Core: Required
  • Phenotyping Core(s): Required

Overall Component

When preparing your application, use Component Type ‘Overall’.

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.

SF424(R&R) Cover (Overall)

Complete entire form.

PHS 398 Cover Page Supplement (Overall)

Note: Human Embryonic Stem Cell lines from other components should be repeated in cell line table in Overall component.

Research & Related Other Project Information (Overall)

Follow standard instructions.

Project/Performance Site Locations (Overall)

Enter primary site only.

A summary of Project/Performance Sites in the Overall section of the assembled application image in eRA Commons compiled from data collected in the other components will be generated upon submission.

Research and Related Senior/Key Person Profile (Overall)

Include only the Project Director/Principal Investigator (PD/PI) and any multi-PDs/PIs (if applicable to this FOA) for the entire application.

A summary of Senior/Key Persons followed by their Biographical Sketches in the Overall section of the assembled application image in eRA Commons will be generated upon submission.

Budget (Overall)

The only budget information included in the Overall component is the Estimated Project Funding section of the SF424 (R&R) Cover.

A budget summary in the Overall section of the assembled application image in eRA Commons compiled from detailed budget data collected in the other components will be generated upon submission.

PHS 398 Research Plan (Overall)

Specific Aims: Please provide overall focus and goals of the proposed Center and describe its overall structure. 

Research Strategy: Provide the rationale for development of the Phenotyping Center and the needs that it will meet. Describe the organizational structure, the participating institutions/organizations, and the roles of all participants. The relationship between individual Cores and their interaction with the Administrative Core, as well as how proposed Cores contribute to the Center and to the overarching theme and goals of the MPMOD program should be defined. Summarize the special features in the environment and/or resources that make this application strong or unique. It may also describe any special relationship between the applicant PC and another applicant PC, such as shared Cores.

Describe activities that could comprise a consortium MPMOD Vibrant program, to be developed during the first year of the award and implemented for years 2-5, aimed at providing pilot funding, phenotyping services or other resources, training, and advice regarding experimental design to young scientists, particularly those from underrepresented groups such as minorities, or from small research institutions that traditionally have not received significant research funding and/or have historically served under-represented populations. These resources are expected to improve the ability of these researchers to compete for independent funding. Vibrant activities should contribute to a diverse, high quality national biomedical research force, eventually helping to reduce US health disparities. Funding for pilot studies and outreach will be in the CU budget, but funding for other elements (waived test fees, structured or unstructured training at the centers, consultation, other mentoring) would be the responsibility of the PCs.

Please also describe any other consortium activities or relationships the applicant feels should be undertaken within MPMOD.

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide.

The following modifications also apply:

All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

Appendix:

Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.

PHS Human Subjects and Clinical Trials Information (Overall)

When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, there must be at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record within the application. The study record(s) must be included in the component(s) where the work is being done, unless the same study spans multiple components. To avoid the creation of duplicate study records, a single study record with sufficient information for all involved components must be included in the Overall component when the same study spans multiple components.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed.

Delayed Onset Study

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.

PHS Assignment Request Form (Overall)

All instructions in the SF424 (R&R) Application Guide must be followed.

Administrative Core

When preparing your application, use Component Type ‘Administrative Core’

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
 

SF424 (R&R) Cover (Administrative Core)

Complete only the following fields:

  • Applicant Information
  • Type of Applicant (optional)
  • Descriptive Title of Applicant’s Project
  • Proposed Project Start/Ending Dates

PHS 398 Cover Page Supplement (Administrative Core)

Enter Human Embryonic Stem Cells in each relevant component.


Research & Related Other Project Information (Administrative Core)

Human Subjects: Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.

Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.

Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
 

Project /Performance Site Location(s) (Administrative Core)

List all performance sites that apply to the specific component.

Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
 

Research & Related Senior/Key Person Profile (Administrative Core)

  • In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Project Lead’ and provide a valid eRA Commons ID in the Credential field.
  • In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
  • Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
  • If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.


Budget (Administrative Core)

Budget forms appropriate for the specific component will be included in the application package.

Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.

Applicants should include requests for travel for Center personnel for an annual MPMOD meeting.


PHS 398 Research Plan (Administrative Core)

Specific Aims: List the broad, long-range objectives of the proposed Core.

Research Strategy:  Describe how the proposed Core activities will contribute to meeting the goals of the Center and national MPMOD program.  Explain the strengths of key personnel and the environment.

Please address the following at a minimum, but it is not necessary to duplicate information found in the Animal Core or Phenotyping Core sections.

Administrative Plan:

  • Administrative structure including a local Steering Committee;
  • The interaction between the Administrative Core and the other Center components, including the local Steering Committee;
  • A succession plan if the PI should leave;
  • Willingness to participate in MPMOD consortium activities including monthly and annual meetings;
  • Willingness to work with other MPMOD PCs and CU to achieve synergy and cost-effectiveness and eliminate unnecessary overlap as possible;
  • Staff management;
  • Communication with clients including: signing of a Conditions of Use Statement (COU) or equivalent provided via the MPMOD website, receipt of orders, providing services, communication of data, billing and collecting payment. It is likely that the MPMOD CU can provide common web-based business tools to support administrative activities if needed;
  • Agreement that any collaborations formed with an MPMOD client that entail the tests being performed for the client, will be at the request of the client and not imposed by MPMOD staff;
  • Records management. The Administrative Core should work closely with the CU to ensure that records are stored appropriately;
  • Data management. All data produced in an MPMOD belong to the client unless other mutually agreeable arrangements are made. The Administrative Core should work closely with the CU to ensure that data are stored safely and appropriately. The Data Sharing Plan should be used to describe data sharing.


Service Plan:

  • Production and maintenance of a test catalog;
  • Consultation services;
  • Public access to test protocols and procedures;
  • Plan for accepting and prioritizing strains for services. The same criteria should be applied to mice from investigators inside and outside the parent institution.


Business Plan:

  • Describe the fee structures and how they are calculated, with the same fee structure applied to academic investigators inside or outside the parent institution. Additional overhead costs are allowed for outside clients, but it must be kept in mind that such overhead costs are likely to come from funding targeted for research (i.e., grant direct costs) and should not constitute an undue burden or a barrier to PC use. Fees can be different for clients from for-profit entities than for those from academic institutions.
  • Agreement that all tests must be paid for by the client, whether inside or outside of the MPMOD or the home institution, with the exception of services provided to underrepresented investigators as part of the MPMOD Vibrant program.
  • Maintain records of program income and spending. Indicate how program income will be used to enhance Center activities and functions, consistent with achieving the goals of the program.


Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:

All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

Appendix:

Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.


PHS Human Subjects and Clinical Trials Information (Administrative Core)

When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed

Delayed Onset Study

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.

 


Animal Core

When preparing your application, use Component Type ‘Core’

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
 

SF424 (R&R) Cover (Animal Core)

Complete only the following fields:

  • Applicant Information
  • Type of Applicant (optional)
  • Descriptive Title of Applicant’s Project
  • Proposed Project Start/Ending Dates
     

PHS 398 Cover Page Supplement (Animal Core)

Enter Human Embryonic Stem Cells in each relevant component.
 

Research & Related Other Project Information (Animal Core)

Human Subjects: Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.

Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.

Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
 

Project /Performance Site Location(s) (Animal Core)

List all performance sites that apply to the specific component.

Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
 

Research & Related Senior/Key Person Profile (Animal Core)

  • In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Project Lead’ and provide a valid eRA Commons ID in the Credential field.
  • In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
  • Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
  • If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.
     

Budget (Animal Core)

Budget forms appropriate for the specific component will be included in the application package.

Funds should not be requested for per diem cage charges for client mice, as these should be paid by the client.

Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
 

PHS 398 Research Plan (Animal Core)

Specific Aims: List the broad, long-range objectives of the proposed Core.

Facilities and Other Resources: Describe the animal facility and the resources that will be available to the MPMOD, including capacity for MPMOD client mice.
 

Research Strategy:

A high-quality Animal Core is an extremely important part of an MPMOD. This section should describe how the proposed Animal Core activities will contribute to meeting the goals of the PC and the national MPMOD program. Explain the strengths of key personnel and the environment.

Please address the following at a minimum, but it is not necessary to duplicate information found above in the Facilities and Other Resources element, or in the Administrative Core or Phenotyping Core sections.

  • Description of animal housing, maintenance, health care and workflows;
  • Germane institution policies needed for reviewer’s assessment of the application;
  • Animal receipt procedures including pathogen testing and quarantine. Institutional quarantine procedures should be clearly conducive for rapid and efficient evaluation of strains being shipped to the MPMOD facility for phenotyping;
  • Anticipated costs for animal care;
  • Special services, or accommodation of tests that can be done within the animal facility itself.
     

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:

All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

 

Appendix:

Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide; any instructions provided here are in addition to the SF424 (R&R) Application Guide instructions.
 

PHS Human Subjects and Clinical Trials Information (Animal Core)

When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed

Delayed Onset Study

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.


Phenotyping Core

When preparing your application, use Component Type ‘Phenotyping Core.’

All instructions in the SF424 (R&R) Application Guide must be followed, with the following additional instructions, as noted.
 

SF424 (R&R) Cover (Phenotyping Core)

Complete only the following fields:

  • Applicant Information
  • Type of Applicant (optional)
  • Descriptive Title of Applicant’s Project
  • Proposed Project Start/Ending Dates
     

PHS 398 Cover Page Supplement (Phenotyping Core)

Enter Human Embryonic Stem Cells in each relevant component.
 

Research & Related Other Project Information (Phenotyping Core)

Human Subjects: Answer only the ‘Are Human Subjects Involved?’ and 'Is the Project Exempt from Federal regulations?’ questions.

Vertebrate Animals: Answer only the ‘Are Vertebrate Animals Used?’ question.

Project Narrative: Do not complete. Note: ASSIST screens will show an asterisk for this attachment indicating it is required. However, eRA systems only enforce this requirement in the Overall component and applications will not receive an error if omitted in other components.
 

Project /Performance Site Location(s) (Phenotyping Core)

List all performance sites that apply to the specific component.

Note: The Project Performance Site form allows up to 300 sites, prior to using additional attachment for additional entries.
 

Research & Related Senior/Key Person Profile (Phenotyping Core)

  • In the Project Director/Principal Investigator section of the form, use Project Role of ‘Other’ with Category of ‘Project Lead’ and provide a valid eRA Commons ID in the Credential field.
  • In the additional Senior/Key Profiles section, list Senior/Key persons that are working in the component.
  • Include a single Biographical Sketch for each Senior/Key person listed in the application regardless of the number of components in which they participate. When a Senior/Key person is listed in multiple components, the Biographical Sketch can be included in any one component.
  • If more than 100 Senior/Key persons are included in a component, the Additional Senior Key Person attachments should be used.


Budget (Phenotyping Core)

Budget forms appropriate for the specific component will be included in the application package.

Note: The R&R Budget form included in many of the component types allows for up to 100 Senior/Key Persons in section A and 100 Equipment Items in section C prior to using attachments for additional entries. All other SF424 (R&R) instructions apply.
 

PHS 398 Research Plan (Phenotyping Core)

Specific Aims: List the broad, long-range objectives of the proposed Core.

Facilities and Other Resources: Describe the core facility and the resources that will be available to the MPMOD.

Research Strategy: Please address the following at a minimum, but it is not necessary to duplicate information found in the Facilities and Other Resources element, or the Administrative Core or Animal Core sections.

Background and Significance: This section should describe how the proposed Phenotyping Core activities will contribute to meeting the goals of the PC and the national MPMOD program. Explain the strengths of key personnel and the environment, and rationale for selection of Phenotyping Core services. Describe how the Phenotyping Core activities will address a compelling and unmet need for the research community. Describe its interaction with other Phenotyping Cores in the proposed PC, and its relationship to similar Cores available in the institution or elsewhere in the US.

Preliminary Studies: Describe germane preliminary data.

Experimental Plan:

  • State the roles and responsibilities of the Core Director, roles of key personnel, and the relationship to other existing Cores in the institution;
  • Describe the proposed test services, including quality control measures, annual capacity and expected usage;
  • Describe consultation services;
  • Include plans for prioritizing services in response to orders.
  • Describe protocols to ensure timely communication to clients of data in an organized, interpretable and error-free format. Describe data maintenance and storage.
  • Describe tests that are planned for development during the project period, and plans for ensuring continued evolution of Phenotyping Core services based on emerging research needs.
  • Describe how program income will be used to advance Phenotyping Core activities or functions.
     

Resource Sharing Plan: Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the SF424 (R&R) Application Guide, with the following modification:

All applications, regardless of the amount of direct costs requested for any one year, should address a Data Sharing Plan.

 

Appendix:

Only limited items are allowed in the Appendix. Follow all instructions for the Appendix as described in the SF424 (R&R) Application Guide.


PHS Human Subjects and Clinical Trials Information (Phenotyping Core)

When involving human subjects research, clinical research, and/or NIH-defined clinical trials follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the SF424 (R&R) Application Guide, with the following additional instructions:

If you answered “Yes” to the question “Are Human Subjects Involved?” on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or a Delayed Onset Study record.

Study Record: PHS Human Subjects and Clinical Trials Information

All instructions in the SF424 (R&R) Application Guide must be followed

Delayed Onset Study

Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start).All instructions in the SF424 (R&R) Application Guide must be followed.

3. Unique Entity Identifier and System for Award Management (SAM)

See Part 1. Section III.1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants.gov

4. Submission Dates and Times

Part I. Overview Information contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission. When a submission date falls on a weekend or Federal holiday, the application deadline is automatically extended to the next business day.

Organizations must submit applications to Grants.gov (the online portal to find and apply for grants across all Federal agencies) using ASSIST or other electronic submission systems. Applicants must then complete the submission process by tracking the status of the application in the eRA Commons, NIH’s electronic system for grants administration. NIH and Grants.gov systems check the application against many of the application instructions upon submission. Errors must be corrected and a changed/corrected application must be submitted to Grants.gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late. Applications that miss the due date and time are subjected to the NIH Policy on Late Application Submission.

Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

Information on the submission process and a definition of on-time submission are provided in the SF424 (R&R) Application Guide.

5. Intergovernmental Review (E.O. 12372)

This initiative is not subject to intergovernmental review.

6. Funding Restrictions

All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Pre-award costs are allowable only as described in the NIH Grants Policy Statement.

7. Other Submission Requirements and Information

Applications must be submitted electronically following the instructions described in the SF424 (R&R) Application Guide. Paper applications will not be accepted.

For information on how your application will be automatically assembled for review and funding consideration after submission go to: http://grants.nih.gov/grants/ElectronicReceipt/files/Electronic_Multi-project_Application_Image_Assembly.pdf.

Applicants must complete all required registrations before the application due date. Section III. Eligibility Information contains information about registration.

For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide. If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. For assistance with application submission, contact the Application Submission Contacts in Section VII.

Important reminders:

All PD(s)/PI(s) and component Project Leads must include their eRA Commons ID in the Credential fieldof the Senior/Key Person Profile Component of the SF424(R&R) Application Package. Failure to register in the Commons and to include a valid PD/PI Commons ID in the credential field will prevent the successful submission of an electronic application to NIH.

The applicant organization must ensure that the DUNS number it provides on the application is the same number used in the organization’s profile in the eRA Commons and for the System for Award Management (SAM). Additional information may be found in the SF424 (R&R) Application Guide.

See more tips for avoiding common errors.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review, NIH. Applications that are incomplete or non-compliant will not be reviewed.

Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review and responsiveness by components of participating organizations, NIH. Applications that are incomplete, non-compliant and/or nonresponsive will not be reviewed.

Use of Common Data Elements in NIH-funded Research

Many NIH ICs encourage the use of common data elements (CDEs) in basic, clinical, and applied research, patient registries, and other human subject research to facilitate broader and more effective use of data and advance research across studies. CDEs are data elements that have been identified and defined for use in multiple data sets across different studies. Use of CDEs can facilitate data sharing and standardization to improve data quality and enable data integration from multiple studies and sources, including electronic health records. NIH ICs have identified CDEs for many clinical domains (e.g., neurological disease), types of studies (e.g. genome-wide association studies (GWAS)), types of outcomes (e.g., patient-reported outcomes), and patient registries (e.g., the Global Rare Diseases Patient Registry and Data Repository). NIH has established a “Common Data Element (CDE) Resource Portal" (https://cde.nlm.nih.gov/home) to assist investigators in identifying NIH-supported CDEs when developing protocols, case report forms, and other instruments for data collection. The Portal provides guidance about and access to NIH-supported CDE initiatives and other tools and resources for the appropriate use of CDEs and data standards in NIH-funded research. Investigators are encouraged to consult the Portal and describe in their applications any use they will make of NIH-supported CDEs in their projects.

Post Submission Materials

Applicants are required to follow the instructions for post-submission materials, as described in the policy. Any instructions provided here are in addition to the instructions in the policy.

Section V. Application Review Information

1. Criteria

Only the review criteria described below will be considered in the review process.  Applications submitted to the NIH in support of the NIH mission are evaluated for scientific and technical merit through the NIH peer review system.

Reviewers will be asked to evaluate the following individual sections.  The overall impact score is not the average for these components.

  • Administrative Core, including leadership of Center and Core Director(s), management, committee structure, business plan and lines of communication.
  • Animal Core, including the capacity to efficiently receive, house and care for an adequate number of mice.
  • Phenotyping Cores, including the potential of the Phenotyping Core to empower diabetes and obesity research in laboratories from outside the home institution as well as inside; the need for the proposed services; qualifications of personnel; management, including prioritization and responsiveness to the needs of the users; quality control management; and any appropriate developmental work.
  • Vibrant Program, including elements that can support the research success of early career scientists, particularly those from underrepresented groups such as minorities, or from small research institutions that traditionally have not received significant research funding and/or have historically served under-represented populations.
Overall Impact - Overall

Reviewers will provide an overall impact score to reflect their assessment of the likelihood for the project to exert a sustained, powerful influence on the research field(s) involved, in consideration of the following review criteria and additional review criteria (as applicable for the project proposed).

Scored Review Criteria - Overall

Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. For example, a project that by its nature is not innovative may be essential to advance a field.

Significance

Does the project address an important problem or a critical barrier to progress in the field? Is the prior research that serves as the key support for the proposed project rigorous? If the aims of the project are achieved, how will scientific knowledge, technical capability, and/or clinical practice be improved? How will successful completion of the aims change the concepts, methods, technologies, treatments, services, or preventative interventions that drive this field?

Specific to this FOA: Does the Phenotyping Center plan to serve a national client base, including investigators outside as well as inside the home institution? Will the national client base benefit from the services/programs supported by the Center, and will proposed services be cost effective? Will the Vibrant program proposed support the research success of early career scientists, particularly those from underrepresented groups such as minorities, or from small research institutions that traditionally have not received significant research funding and/or have historically served under-represented populations?

Investigator(s)

Are the PD(s)/PI(s), collaborators, and other researchers well suited to the project? If Early Stage Investigators or those in the early stages of independent careers, do they have appropriate experience and training? If established, have they demonstrated an ongoing record of accomplishments that have advanced their field(s)? If the project is collaborative or multi-PD/PI, do the investigators have complementary and integrated expertise; are their leadership approach, governance and organizational structure appropriate for the project?

Specific to this FOA: Are the scientific and administrative leadership abilities of the proposed Center and Core Directors appropriate?  Do they plan to devote adequate time to the effective management of the Phenotyping Center? Are they likely to be collaborative with the staff in other MPMOD Phenotyping Centers and the Coordinating Unit?

Innovation

Does the application challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions? Are the concepts, approaches or methodologies, instrumentation, or interventions novel to one field of research or novel in a broad sense? Is a refinement, improvement, or new application of theoretical concepts, approaches or methodologies, instrumentation, or interventions proposed?

Specific to this FOA:  Do the Phenotyping Cores propose innovative methods, techniques, and/or resources that are not easily available to all US researchers who employ mouse models to study diabetes, obesity and other metabolic diseases? Do the Cores demonstrate the ability to adapt when needed to support investigators? Does the proposed Vibrant program contain innovative approaches to support the research success of early career scientists, particularly those from underrepresented groups such as minorities, or from small research institutions that traditionally have not received significant research funding and/or have historically served under-represented populations?  

Approach

Are the overall strategy, methodology, and analyses well-reasoned and appropriate to accomplish the specific aims of the project? Have the investigators included plans to address weaknesses in the rigor of prior research that serves as the key support for the proposed project? Have the investigators presented strategies to ensure a robust and unbiased approach, as appropriate for the work proposed? Are potential problems, alternative strategies, and benchmarks for success presented? If the project is in the early stages of development, will the strategy establish feasibility and will particularly risky aspects be managed? Have the investigators presented adequate plans to address relevant biological variables, such as sex, for studies in vertebrate animals or human subjects?

Specific to this FOA: Are the Administrative Core plan and staff appropriate to manage the overall MPMOD Phenotyping Center?  Is there an appropriate plan for receipt of orders and mice, conducting tests, and communicating results back to clients?  Does the Animal Core have an appropriate plan, staff, and space to be able to receive, test and care for mice shipped from outside clients?  Have the Phenotyping Cores proposed services of high scientific and technical quality, and are they feasible?  Are staff adequately trained and supervised?  Will the proposed services be valuable to the US researchers who employ mice to study diabetes and obesity?  Will outside investigators have adequate access to these services?  Is the fee structure appropriate, both for clients and to ensure the Phenotyping Center can provide the proposed services?

If the project involves human subjects and/or NIH-defined clinical research, are the plans to address 1) the protection of human subjects from research risks, and 2) inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion or exclusion of individuals of all ages (including children and older adults), justified in terms of the scientific goals and research strategy proposed?

Environment

Will the scientific environment in which the work will be done contribute to the probability of success? Are the institutional support, equipment and other physical resources available to the investigators adequate for the project proposed? Will the project benefit from unique features of the scientific environment, subject populations, or collaborative arrangements?

Specific to this FOA: Is there evidence of institutional commitment to the Center program? Is the physical space, particularly of the Animal Core and the Phenotyping Cores, appropriate for the proposed activities, and does it afford the potential for sufficient capacity?  Will the environment support the activities proposed for the Vibrant program?

Additional Review Criteria - Overall

As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

Protections for Human Subjects

For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1) risk to subjects, 2) adequacy of protection against risks, 3) potential benefits to the subjects and others, 4) importance of the knowledge to be gained, and 5) data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1) the justification for the exemption, 2) human subjects involvement and characteristics, and 3) sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

Inclusion of Women, Minorities, and Individuals Across the Lifespan

When the proposed project involves human subjects and/or NIH-defined clinical research, the committee will evaluate the proposed plans for the inclusion (or exclusion) of individuals on the basis of sex/gender, race, and ethnicity, as well as the inclusion (or exclusion) of individuals of all ages (including children and older adults) to determine if it is justified in terms of the scientific goals and research strategy proposed. For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research.

Vertebrate Animals

The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: (1) description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; (2) justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; (3) interventions to minimize discomfort, distress, pain and injury; and (4) justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals. Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section.

Biohazards

Reviewers will assess whether materials or procedures proposed are potentially hazardous to research personnel and/or the environment, and if needed, determine whether adequate protection is proposed.

Resubmissions

Not Applicable

Renewals

Not Applicable

Revisions

Not Applicable

Additional Review Considerations - Overall

As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

Applications from Foreign Organizations

Not Applicable

Select Agent Research

Reviewers will assess the information provided in this section of the application, including 1) the Select Agent(s) to be used in the proposed research, 2) the registration status of all entities where Select Agent(s) will be used, 3) the procedures that will be used to monitor possession use and transfer of Select Agent(s), and 4) plans for appropriate biosafety, biocontainment, and security of the Select Agent(s).

Resource Sharing Plans

Reviewers will comment on whether the following Resource Sharing Plans, or the rationale for not sharing the following types of resources, are reasonable: (1) Data Sharing Plan; (2) Sharing Model Organisms; and (3) Genomic Data Sharing Plan (GDS).

Authentication of Key Biological and/or Chemical Resources:

For projects involving key biological and/or chemical resources, reviewers will comment on the brief plans proposed for identifying and ensuring the validity of those resources.

Budget and Period of Support

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research.

2. Review and Selection Process

Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by NIDDK, in accordance with NIH peer review policy and procedures, using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

As part of the scientific peer review, all applications will receive a written critique.

Applications may undergo a selection process in which only those applications deemed to have the highest scientific and technical merit (generally the top half of applications under review) will be discussed and assigned an overall impact score.

Appeals of initial peer review will not be accepted for applications submitted in response to this FOA.

Applications will be assigned to the appropriate NIH Institute or Center. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Diabetes and Digestive and Kidney Diseases Advisory Council (NDDKAC). The following will be considered in making funding decisions:

  • Scientific and technical merit of the proposed project as determined by scientific peer review.
  • Availability of funds.
  • Relevance of the proposed project to program priorities.

3. Anticipated Announcement and Award Dates

After the peer review of the application is completed, the PD/PI will be able to access his or her Summary Statement (written critique) via the eRA Commons. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

Information regarding the disposition of applications is available in the NIH Grants Policy Statement.

Section VI. Award Administration Information

1. Award Notices

If the application is under consideration for funding, NIH will request "just-in-time" information from the applicant as described in theNIH Grants Policy Statement.

A formal notification in the form of a Notice of Award (NoA) will be provided to the applicant organization for successful applications. The NoA signed by the grants management officer is the authorizing document and will be sent via email to the recipient's business official.

Recipients must comply with any funding restrictions described in Section IV.6. Funding Restrictions. Selection of an application for award is not an authorization to begin performance. Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

Any application awarded in response to this FOA will be subject to terms and conditions found on the Award Conditions and Information for NIH Grants website. This includes any recent legislation and policy applicable to awards that is highlighted on this website.

Individual awards are based on the application submitted to, and as approved by, the NIH and are subject to the IC-specific terms and conditions identified in the NoA.

Institutional Review Board or Independent Ethics Committee Approval: Grantee institutions must ensure that protocols are reviewed by their IRB or IEC. To help ensure the safety of participants enrolled in NIH-funded studies, the recipient must provide NIH copies of documents related to all major changes in the status of ongoing protocols.

2. Administrative and National Policy Requirements

All NIH grant and cooperative agreement awards include the NIH Grants Policy Statement as part of the NoA. For these terms of award, see the NIH Grants Policy Statement Part II: Terms and Conditions of NIH Grant Awards, Subpart A: Generaland Part II: Terms and Conditions of NIH Grant Awards, Subpart B: Terms and Conditions for Specific Types of Grants, Recipients, and Activities, including of note, but not limited to:

If a recipient is successful and receives a Notice of Award, in accepting the award, the recipient agrees that any activities under the award are subject to all provisions currently in effect or implemented during the period of the award, other Department regulations and policies in effect at the time of the award, and applicable statutory provisions.

Recipients of federal financial assistance (FFA) from HHS must administer their programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age and, in some circumstances, religion, conscience, and sex. This includes ensuring programs are accessible to persons with limited English proficiency. The HHS Office for Civil Rights provides guidance on complying with civil rights laws enforced by HHS. Please see https://www.hhs.gov/civil-rights/for-providers/provider-obligations/index.html and http://www.hhs.gov/ocr/civilrights/understanding/section1557/index.html.

HHS recognizes that research projects are often limited in scope for many reasons that are nondiscriminatory, such as the principal investigator’s scientific interest, funding limitations, recruitment requirements, and other considerations. Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research. For additional guidance regarding how the provisions apply to NIH grant programs, please contact the Scientific/Research Contact that is identified in Section VII under Agency Contacts of this FOA.

Please contact the HHS Office for Civil Rights for more information about obligations and prohibitions under federal civil rights laws at https://www.hhs.gov/ocr/about-us/contact-us/index.html or call 1-800-368-1019 or TDD 1-800-537-7697.

In accordance with the statutory provisions contained in Section 872 of the Duncan Hunter National Defense Authorization Act of Fiscal Year 2009 (Public Law 110-417), NIH awards will be subject to the Federal Awardee Performance and Integrity Information System (FAPIIS) requirements. FAPIIS requires Federal award making officials to review and consider information about an applicant in the designated integrity and performance system (currently FAPIIS) prior to making an award. An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. The Federal awarding agency will consider any comments by the applicant, in addition to other information in FAPIIS, in making a judgement about the applicant’s integrity, business ethics, and record of performance under Federal awards when completing the review of risk posed by applicants as described in 45 CFR Part 75.205 and 2 CFR Part 200.206 “Federal awarding agency review of risk posed by applicants.” This provision will apply to all NIH grants and cooperative agreements except fellowships.

Cooperative Agreement Terms and Conditions of Award

The following special terms of award are in addition to, and not in lieu of, otherwise applicable U.S. Office of Management and Budget (OMB) administrative guidelines, U.S. Department of Health and Human Services (DHHS) grant administration regulations at 45 CFR Part 75, 2 CFR 200, and other HHS, PHS, and NIH grant administration policies.

The administrative and funding instrument used for this program will be the cooperative agreement, an "assistance" mechanism (rather than an "acquisition" mechanism), in which substantial NIH programmatic involvement with the recipients is anticipated during the performance of the activities. Under the cooperative agreement, the NIH's purpose is to support and stimulate the recipients' activities by involvement in and otherwise working jointly with the award recipients in a partnership role; it is not to assume direction, prime responsibility, or a dominant role in the activities. Consistent with this concept, the dominant role and prime responsibility reside with the recipients for the project as a whole, although specific tasks and activities may be shared among the recipients and the NIH as defined below.

The MPMOD consists of a number of Phenotyping Centers and a Coordinating Unit, with a Steering Committee and a panel of External Consultants.

  • Recipient(s) will be primarily responsible for defining the objectives and approaches, planning, conducting, analyzing, and publishing of results, interpretations, and conclusions of studies conducted under the terms and conditions of the cooperative agreement award.
  • The Program Director/Principal Investigator (PD/PI) will assume responsibility and accountability to the applicant organization officials and to the NIH for the performance and proper conduct of the research supported under this Funding Opportunity Announcement (FOA) in accordance with the terms and conditions of the award, as well as all pertinent laws, regulations and policies.
  • Recipient(s) will retain custody of and have primary rights to the data and software developed under these awards, subject to Government policies regarding rights of access consistent with current DHHS, PHS, and NIH policies.
  • Recipients are responsible for their staff in maintaining the confidentiality of the information as developed by the consortium, including, without limitation, study protocols, data analysis, conclusions, etc. per policies approved by the Steering Committee (SC) as well as any confidential information received by third party collaborators.
  • Recipients must analyze, publish and/or publicly release and disseminate results, data and other products of the study in a timely manner, concordant with the approved plan for making quality-assured data and materials available to the scientific community and the NIH, consistent with NIH policies and achieving the goals of the FOA.
  • Recipient(s) will be required to participate in a cooperative and interactive manner with members of the consortium including designated NIH staff (e.g., Program Official, Project Scientist).
  • Recipients must share data, materials, models, methods, information and unique research resources that are generated by the projects in concordance with MPMOD Consortium policies in order to facilitate progress. When appropriate, and in accordance with NIH policies, as well as NIDDK policies, awardees will be expected to collaborate; share novel reagents, biomaterials, methods and models, and resources; and share both positive and negative results that would help guide the research activities of other MPMOD members.
  • Recipient(s) agree to establish agreements amongst themselves that address the following issues: (1) procedures for data sharing among consortium members and data sharing with industry partners; (2) procedures for safeguarding confidential information, including without limitation, any data generated by the consortium as well as information and/or data received from external collaborators; (3) procedures for addressing ownership of intellectual property that result from aggregate multi-party data; (4) procedures for sharing bio-specimens under an overarching MTA amongst consortium members that operationalizes material transfer in an efficient and expeditious manner; (5) procedures for reviewing publications, determining authorship, and industry access to publications.
  • Any third-party collaboration (including but not limited to interactions with organizations from industry, academia, and nonprofit institutions) should be governed by a research collaboration agreement (e.g., Clinical Trial Agreement, Research Collaborative Agreement, etc.) or any third-party contract mechanism(s) with terms that ensure the collaboration is conducted in accordance with the Cooperative Agreement, network policies, applicable NIH/NIDDK policies and procedures, and with written approval from NIDDK Program staff. Any relevant proposed third-party agreements related to the network studies between the grantee and the third party will be provided to the NIDDK Program staff and NIDDK Technology Advancement Office for review, comment, and approval to assure compliance with NIH/NIDDK policies and network policies. Further, at the request of the NIDDK Program staff, any other network-relevant third-party agreements must be shared with NIDDK. Failure to comply with this term may prompt action in accordance with NIH Grants Policy Statement, Section 8.5 titled: “Special Award Conditions and Remedies for Noncompliance (Special Award Conditions and Enforcement Actions”, and Section 8.5.2, titled: “Remedies for Noncompliance or Enforcement Actions: Suspension, Termination, and Withholding Support”, noncompliance with the terms and conditions of award will be considered by the funding IC for future funding and support decisions and may result in termination of the award.
  • Recipients must agree to comply with the processes and goals as delineated within the FOA.
  • Upon completion or termination of the research project(s), the recipients are responsible for making all study materials and procedures broadly available (e.g., putting into the public domain) or making them accessible to the research community according to the NIH-approved plan submitted for each project, for making data and materials available to the scientific community and the NIH for the conduct of research. Data Management and Sharing Plan: In accordance with the NIH Policy for Data Management and Sharing (NIH NOT-OD-21-013), the NIDDK approved plan will become a term and condition of award, be routinely monitored during the award period, and compliance may factor into future funding decisions.  By the end of the funding or proprietary period, an recipient or study group may not continue to use or share study-generated resources until those resources are available to the public via an NIDDK approved repository per the NIDDK approved sharing plan.  
  • Recipient(s) agree to the governance of the study through a Steering Committee:
    • The PD/PI, or contact PD/PI in the case of multi-PD/PI awards, will serve as a voting member of the Steering Committee and will attend all meetings of the Steering Committee.
    • Each full member will have one vote.
    • The recipient will be responsible for accepting and implementing the goals, priorities, procedures, protocols, and policies agreed upon by the Steering Committee and Subcommittees.
    • Recipients must serve on MPMOD subcommittees as needed. Subcommittees will report progress at Steering Committee Meetings and/or lead discussions at the Annual Investigator’s Retreat.
  • Recipients may be asked to scientifically review applications for special opportunity pool funds, as it is deemed appropriate.

NIH staff have substantial programmatic involvement that is above and beyond the normal stewardship role in awards, as described below:

  • The NIDDK will designate program staff, including a Program Official and a Grants Management Specialist to provide normal program stewardship and administrative oversight of the cooperative agreement. The Program Official and Grants Management Specialist will be named in the Notice of Grant Award.
  • The NIDDK will invite External Consultants with relevant scientific expertise. The External Consultants [or External Experts] will meet to review the progress of the research projects and to advise NIH staff of scientific developments and opportunities that may enhance the achievement of the study goals.
  • An NIH IC Project Scientist [or Project Coordinator, or Project Collaborator] will be substantially involved in this project above and beyond the normal stewardship of an NIH IC Program Official as follows:
    • The NIH Project Scientist(s) will coordinate and facilitate the research projects, attend and participate in all meetings of the Consortium (Steering Committee), and act as (a) liaisons between the Recipient (Steering Committee) and the External Consultants [External Experts].

    • The NIH Project Scientist(s) will be a member(s) of the Steering Committee and, as determined by that committee, and its Subcommittees as needed. Only one NIH Project Scientist will vote on the Steering Committee. Other designated NIH program staff attending the steering committee meetings will be ex officio (non-voting) member(s).

    • The NIH Project Scientist and other designated NIH program staff will help the Steering Committee develop and draft operating policies.

    • The NIH Project Scientist(s) and Program Official will review the scientific progress, cooperation in carrying out research, and maintenance of high-quality research in each of the individual research project(s), and review the project(s) for compliance with operating policies developed by the Consortium (Steering Committee), and may recommend to the NIH to continue funding; withhold support or restrict an award for lack of scientific progress or failure to adhere to policies established by the Consortium (Steering Committee). Review of progress may include regular communications with the PD/PI and NIH staff, periodic site visits for discussions with recipient research teams, fiscal review, and other relevant matters. The NIH retains the option of periodic external review of progress.

    • The NIDDK reserves the right to terminate or curtail any study or any individual award in the event of (a) substantial shortfall in data collection or submission, quality control, or other major breach or a study protocol or Consortium policy and procedure, (b) substantive changes in a study protocol that are not in keeping with the objectives of the FOA, and/or a human subject ethical issues that may dictate a premature termination.

    • The NIH Project Scientist(s) and Program Official will review and approve applications of the Special Opportunity Funds to ensure that they are within the scope of Consortium research as described in the FOA and NIH guidelines.

    • The NIH will name additional scientific consultants as necessary from within the NIH whose function will be to assist the Project Scientist(s) and the Steering Committee in carrying out the goals and aims of the approved studies. The NIH will have one vote for any key committees, regardless of the number of NIH personnel involved.

    • The Project Scientist(s) will have substantial scientific programmatic involvement in quality control, preparation of publications, research coordination and performance monitoring. The Project Scientist(s) will have the same access and privileges to any data generated by the grantee. The dominant role and primary responsibility for these activities reside with the recipients for the project as a whole, although specific tasks and activities in carrying out the studies will be shared among the awardees and the NIDDK Project Scientist(s).

    • The NIH Project Scientist(s) serve as a resource with respect to other ongoing NIH activities that may be relevant to the MPMOD studies to facilitate compatibility and avoid unnecessary duplication of effort.

    • The NIH Project Scientist(s) or designee may coordinate activities among recipients by assisting in the design, development, and coordination of (a) common research protocol(s) and statistical evaluations of data and in the publication of results.

    • The NIH Project Scientist(s) may review procedures for assessing data quality and monitor study performance.

    • The NIH Project Scientist(s) may be (a) co-author(s) on study publications. In general, to warrant co-authorship, the NIH staff must have contributed to one or more of the following areas: (a) design of the concepts or experiments being tested; (b) performance of significant portions of the activity; (c) participation in analysis and interpretation of study results and (d) preparation and authorship of pertinent manuscripts.

Areas of Joint Responsibility include:

Through the Recipient, (Steering Committee) and NIH staff, the study members will cooperatively develop and implement processes to submit information and data to the Coordinating Center (CC), determine criteria and processes for quality control of information and data to be posted for the research community, refine scientific objectives, and implement research advances to facilitate the goals of the study, consistent with NIH policies and achieving the goals of the program as described in the FOA.

  • Executive Committee (EC)
  • The EC will consist of: The Director of the MPMOD CC, the NIDDK Project Scientist(s), and representative PIs are chosen among the Recipients; the EC is not a governing body and does not cast votes.
  • The EC will review the progress of all NIH-funded special funding opportunity programs and make recommendations for improvement. Annual reports will be prepared for each special funding opportunity to coincide with one of the annual SC meetings;
  • The EC will be responsible for organizing the yearly MPMOD Scientific Retreat.
  • The EC will have meetings that will be organized by the Director of the MPMOD CC. Any EC member may place items on the agenda. These should be communicated in advance of the meeting to the Project Scientist(s) who will distribute these to all members. The designated NIDDK Program Official(s) of U2C may be asked to participate in order to provide additional information and to summarize actions that are taken.
  • Steering Committee (SC)
  • The Steering Committee (SC) composed of each of the PD/PI(s) for each U2C, or Contact PD/PI(s) in the case of multi-PD/PI grants, of the study (including research projects and Coordinating Center) and the NIH Project Scientist(s) will be the main governing board of the study (Consortium). Each full SC member will have one vote. All major scientific and policy decisions will be determined by (voting policies as established by the SC at the initial meeting). This committee will operate to develop collaborative protocols, identify impediments to success and strategies to overcome them, develop shared tools for disseminating information about the projects, and identify opportunities for sharing techniques, materials, information and tools developed within each individual project. The SC activities and decisions will consider the advice of the External Consultants [External Experts].
  • NIDDK staff, in concert with the SC, will have the option to redirect research activities within the U2C grant(s) if it is considered beneficial to the overall program.
  • The SC may, as it deems necessary, invite additional, non-voting scientific consultants to meetings at which research priorities and opportunities are discussed. The NIH reserves the right to augment the expertise of the Steering Committee when necessary.
  • There will be (an initial) meeting and one in-person Steering Committee meeting annually, in addition to regular virtual meetings. These meetings will incorporate participation and recommendations of the External Consultants when determined by NIH staff (or as stipulated in the FOA).
  • An SC Chairperson will be chosen by the NIH. In collaboration with the CC and the NIH Project Scientists, the Chairperson is responsible for coordinating the SC activities, for preparing meeting agendas and for chairing meetings.
  • The SC, including the Project Scientist(s), is responsible for establishing and implementing processes and criteria for recommending special projects for consideration for special opportunity funds by NIH staff.
  • Each research project recipient and the CC recipient agree to the governance of the U2C through the SC.
  • The NIH Project Scientist(s) may work with recipients on issues coming before the Steering Committee and, as appropriate, other committees.
  • External Consultants
  • An independent panel of External Consultants will be established by the NIDDK. The External Experts will review periodically the interim progress of the U2Cs and report to NIDDK staff. Members of the panel of External Experts may be asked, on an ad hoc basis, to participate in the peer review of applications for new research initiatives that utilize special “opportunity pool” funds.

Dispute Resolution:

Any disagreements that may arise in scientific or programmatic matters (within the scope of the award) between award recipients and the NIH may be brought to Dispute Resolution. A Dispute Resolution Panel composed of three members will be convened. It will have three members: a designee of the Steering Committee chosen without NIH staff voting, one NIH designee, and a third designee with expertise in the relevant area who is chosen by the other two; in the case of individual disagreement, the first member may be chosen by the individual recipient. This special dispute resolution procedure does not alter the recipient's right to appeal an adverse action that is otherwise appealable in accordance with PHS regulation 42 CFR Part 50, Subpart D and DHHS regulation 45 CFR Part 16.

3. Reporting

When multiple years are involved, recipients will be required to submit the Research Performance Progress Report (RPPR) annually and financial statements as required in the NIH Grants Policy Statement.

A final RPPR, invention statement, and the expenditure data portion of the Federal Financial Report are required for closeout of an award, as described in the NIH Grants Policy Statement. NIH FOAs outline intended research goals and objectives. Post award, NIH will review and measure performance based on the details and outcomes that are shared within the RPPR, as described at 45 CFR Part 75.301 and 2 CFR Part 200.301.

The Federal Funding Accountability and Transparency Act of 2006 (Transparency Act), includes a requirement for recipients of Federal grants to report information about first-tier subawards and executive compensation under Federal assistance awards issued in FY2011 or later. All recipients of applicable NIH grants and cooperative agreements are required to report to the Federal Subaward Reporting System (FSRS) available at www.fsrs.gov on all subawards over the threshold. See the NIH Grants Policy Statement for additional information on this reporting requirement.

In accordance with the regulatory requirements provided at 45 CFR 75.113and 2 CFR Part 200.113 and Appendix XII to 45 CFR Part 75 and 2 CFR Part 200, recipients that have currently active Federal grants, cooperative agreements, and procurement contracts from all Federal awarding agencies with a cumulative total value greater than $10,000,000 for any period of time during the period of performance of a Federal award, must report and maintain the currency of information reported in the System for Award Management (SAM)about civil, criminal, and administrative proceedings in connection with the award or performance of a Federal award that reached final disposition within the most recent five-year period. The recipient must also make semiannual disclosures regarding such proceedings. Proceedings information will be made publicly available in the designated integrity and performance system (currently FAPIIS). This is a statutory requirement under section 872 of Public Law 110-417, as amended (41 U.S.C. 2313). As required by section 3010 of Public Law 111-212, all information posted in the designated integrity and performance system on or after April 15, 2011, except past performance reviews required for Federal procurement contracts, will be publicly available. Full reporting requirements and procedures are found in Appendix XII to 45 CFR Part 75and 2 CFR Part 200 – Award Term and Condition for Recipient Integrity and Performance Matters.

Section VII. Agency Contacts

We encourage inquiries concerning this funding opportunity and welcome the opportunity to answer questions from potential applicants.

Application Submission Contacts

eRA Service Desk (Questions regarding ASSIST, eRA Commons, application errors and warnings, documenting system problems that threaten submission by the due date, and post-submission issues)

Finding Help Online: http://grants.nih.gov/support/ (preferred method of contact)
Telephone: 301-402-7469 or 866-504-9552 (Toll Free)

General Grants Information (Questions regarding application instructions, application processes, and NIH grant resources)
Email: GrantsInfo@nih.gov (preferred method of contact)
Telephone: 301-945-7573

Grants.gov Customer Support (Questions regarding Grants.gov registration and Workspace)
Contact Center Telephone: 800-518-4726
Email: support@grants.gov

Scientific/Research Contact(s)

Kristin Abraham, Ph.D.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-451-8048
Email: kristin.abraham@nih.gov

Peer Review Contact(s)

Ann A. Jerkins, PhD
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-2242
Email: Ann.Jerkins@nih.gov

Financial/Grants Management Contact(s)

Christina Coriz
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Telephone: 301-594-8848
Email: corizc@mail.nih.gov

Section VIII. Other Information

Recently issued trans-NIH policy notices may affect your application submission. A full list of policy notices published by NIH is provided in the NIH Guide for Grants and Contracts. All awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement.

Authority and Regulations

Awards are made under the authorization of Sections 301 and 405 of the Public Health Service Act as amended (42 USC 241 and 284) and under Federal Regulations 42 CFR Part 52 and 45 CFR Part 75 and 2 CFR Part 200.

NIH Office of Extramural Research Logo
Department of Health and Human Services (HHS) - Home Page
Department of Health
and Human Services (HHS)
USA.gov - Government Made Easy
NIH... Turning Discovery Into Health®


Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files.